Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age

Stage I of this study (NCT04142242) demonstrated the safety and immunogenicity of a booster dose of a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) and immune persistence 3 and 6–7 years after priming in older adults who received either quadrivalent meningococcal...

Full description

Saved in:
Bibliographic Details
Main Authors: Corwin A. Robertson, Jeffry Jacqmein, Alexandre Selmani, Katherine Galarza, Philipp Oster
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Antibody persistence
booster
elderly
immunogenicity
MenACYW-TT booster
quadrivalent meningococcal conjugate vaccine
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2426868
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items